A retrospective multicenter efficacy study of patients treated with conditioning regimen and low-dose azacitidine maintenance after allogeneic hematopoietic cell transplantation (HCT) for acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS)
Latest Information Update: 17 May 2021
At a glance
- Drugs Azacitidine (Primary)
- Indications Acute myeloid leukaemia; Myelodysplastic syndromes
- Focus Therapeutic Use
- 17 May 2021 New trial record